Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression

CNS Spectr. 2008 Jun;13(6):511-4. doi: 10.1017/s1092852900016746.

Abstract

Varenicline is a promising agent with demonstrated efficacy in the promotion of smoking cessation. However, from the time of initial trials, it has been associated with significant psychiatric adverse effects. We describe a case where mixed mood and psychotic disturbance developed in an individual with a history of depression and a family history of bipolar disorder. Based on this case, we hypothesize a possible mechanism of action for these adverse effects and preventive measures that could be undertaken in its effective use.

Publication types

  • Case Reports

MeSH terms

  • Antipsychotic Agents / therapeutic use
  • Aripiprazole
  • Benzazepines / adverse effects*
  • Benzazepines / therapeutic use
  • Bipolar Disorder / chemically induced*
  • Bipolar Disorder / diagnosis
  • Bipolar Disorder / genetics
  • Bipolar Disorder / psychology
  • Depressive Disorder / diagnosis
  • Depressive Disorder / genetics*
  • Depressive Disorder / psychology
  • Depressive Disorder / therapy
  • Female
  • Genetic Predisposition to Disease / genetics
  • Humans
  • Middle Aged
  • Piperazines / therapeutic use
  • Psychoses, Substance-Induced / diagnosis
  • Psychoses, Substance-Induced / drug therapy
  • Psychoses, Substance-Induced / genetics*
  • Psychoses, Substance-Induced / psychology
  • Psychotherapy
  • Quinolones / therapeutic use
  • Quinoxalines / adverse effects*
  • Quinoxalines / therapeutic use
  • Smoking Cessation*
  • Stress, Psychological / complications
  • Varenicline

Substances

  • Antipsychotic Agents
  • Benzazepines
  • Piperazines
  • Quinolones
  • Quinoxalines
  • Aripiprazole
  • Varenicline